Stereotactic Body Radiotherapy for Spine Tumors
Stereotactic Body Radiotherapy for Spine Tumors
This study will evaluate the local control rate as well as acute and late toxicity rates of
 stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine
 tumors.
This study is a single site, non-randomized, prospective, phase IV trial. Patients are
 composed of 2 groups:Spine Metastases OR Benign Spine Tumors. Data collected will include
 patient demographics, pathology data, tumor stage, SBRT dose fractionation scheme, dose
 received by adjacent critical normal tissues, tumor recurrence data, and acute and late
 toxicities.

 Follow up data will be collected during the patient's standard office visits. The anticipated
 duration of this study is 5 years
Eligibility Criteria:

 -  Patient age >= 18 years

 -  performance status of 0-3

 -  Vertebral and/or paraspinal metastases, with or without prior surgery and/or
 fractionated radiotherapy

 -  Benign extradural spine tumors such as chordomas, meningiomas, schwannomas,
 neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).

 -  Established histologic diagnosis of a benign or malignant tumor of the spine.

 -  Arteriovenous malformation of the spine identified radiographically (no biopsy)

 -  Well-defined lesion involving no more than 2 adjacent vertebral levels or spinal
 segment

 -  Minimal spinal canal compromise that is not rapidly progressive. Ideally, the tumor
 should not be within 5 mm of the spinal cord.

 -  If chemotherapy is planned, ideally it should not have been given within 30 days of
 starting radiation and should not resume until at least 2 weeks after completing
 radiation. In addition, it is not recommended to perform SBRT when targeted
 anti-angiogenesis therapy is planned within 2 months of the procedure.

 -  Signed study-specific consent form

 Exclusion Criteria:

 -  Lesion involving > 3 adjacent vertebral levels

 -  Overt spinal instability

 -  Neurologic deficit due to bony fragments/bony compression of neural structures

 -  Prior radiotherapy at the involved level(s) within 3 months of radiosurgery, more than
 one prior course of radiotherapy at the involved level(s), or more than 45 Gy previous
 radiation exposure at the involved level(s)

 -  Rapidly progressive spinal cord compromise or neurological deficit

 -  Paralysis, or otherwise compromised motor function due to radiographically confirmed
 cord compression

 -  Patient unable to undergo an MRI

 -  Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown
 effects of RT on lactating females

 -  Patients with psychiatric or addictive disorder that would preclude obtaining informed
 consent